The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia
The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia: A Preliminary Report of Short Term Follow up
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Outside U.S./Canada
-
Mansoura, Outside U.S./Canada, Egypt, 35516
- Gomhoria Street
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >18 years.
- Fever ≥ 38º C with upper respiratory tract manifestations, generalized bone ache with or without gastrointestinal symptoms as diarrhea.
- Chest CT with signs suggestive of COVID-19.
- Mild and moderate cases of COVID-19 pneumonia with respiratory and hemodynamic stability. - High C reactive protein (CRP).- With or without history of contact with index case who is isolated in a governmental hospital assigned for treatment of patients proved to have RT-PCR positive test for COVID-19
- With or without abnormalities in the total or differential white cell count.
- Welling to sign a fully informed consent.
Exclusion Criteria:
- Severe and critical illness with respiratory failure and/ or hemodynamic instability.
- CT with pleural effusion with or without lung cavitation.
- Other organ failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Sodium Bicarbonate
Inhalation of Sodium Bicarbonate 8.4% via nebulizer
|
Inhalation of Sodium Bicarbonate 8.4% via nebulizer
|
|
Placebo Comparator: Control
placebo
|
Inhalation of Sodium Bicarbonate 8.4% via nebulizer
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to clinical recovery
Time Frame: 7 days
|
defined as return of body temperature and relief of cough for more than 72 hours measured in days
|
7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulmonary recovery status
Time Frame: 7 days
|
assessed by Chest CT defined as exacerbated, unchanged, moderately improved (with less than 50% pneumonia resolved) and significantly improved (with more than 50% pneumonia resolved).
|
7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mohammed K Elbadrawy, PhD, Chest department Mansoura University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Sodium Bicarbonate COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
NCT00610324CompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated Pneumonia
-
NCT03006679WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
NCT06168734WithdrawnHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
NCT07354425CompletedPneumococcal Pneumonia | Community Acquired Pneumonia (CAP)
-
NCT01808092CompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)
-
NCT00543608TerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
NCT04952337UnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious Organisms
-
NCT03348579CompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired Pneumonia
-
NCT06430008Enrolling by invitationSialic Acid | Superoxide Dismutase | Lipid Pneumonia
-
NCT07512596Not yet recruitingHospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia
Clinical Trials on Sodium Bicarbonate
-
NCT01458873Unknown
-
NCT07273539Completed
-
NCT02521181Completed
-
NCT00484354CompletedRenal Replacement Therapy | Kidney Failure, Acute
-
NCT02743650TerminatedChronic Kidney Disease
-
NCT00312117CompletedKidney Diseases | Contrast Induced Nephropathy
-
NCT00424320UnknownAcute Kidney Failure
-
NCT02896309CompletedChronic Kidney Disease